Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Joseph A. Sparano, Jeannette Y. Lee, Lawrence D. Kaplan, Alexandra M. Levine, Juan Carlos Ramos, Richard F. Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H. Henry, Jamie Von Roenn, Bruce J. Dezube, Scot C. Remick, Manisha H. Shah, Lawrence Leichman, Lee Ratner, Ethel Cesarman, Amy Chadburn, Ronald Mitsuyasu

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIV-associated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm.We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.gov as NCT00049036.

Original languageEnglish (US)
Pages (from-to)3008-3016
Number of pages9
JournalBlood
Volume115
Issue number15
DOIs
StatePublished - Apr 15 2010

Fingerprint

Chemotherapy
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cells
HIV
Drug Therapy
Vincristine
Etoposide
Prednisone
Doxorubicin
Cyclophosphamide
Toxicity
Confidence Intervals
CD4 Lymphocyte Count
Intravenous Infusions
Lymphoma
Mortality
Rituximab
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Sparano, J. A., Lee, J. Y., Kaplan, L. D., Levine, A. M., Ramos, J. C., Ambinder, R. F., ... Mitsuyasu, R. (2010). Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood, 115(15), 3008-3016. https://doi.org/10.1182/blood-2009-08-231613

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. / Sparano, Joseph A.; Lee, Jeannette Y.; Kaplan, Lawrence D.; Levine, Alexandra M.; Ramos, Juan Carlos; Ambinder, Richard F.; Wachsman, William; Aboulafia, David; Noy, Ariela; Henry, David H.; Von Roenn, Jamie; Dezube, Bruce J.; Remick, Scot C.; Shah, Manisha H.; Leichman, Lawrence; Ratner, Lee; Cesarman, Ethel; Chadburn, Amy; Mitsuyasu, Ronald.

In: Blood, Vol. 115, No. 15, 15.04.2010, p. 3008-3016.

Research output: Contribution to journalArticle

Sparano, JA, Lee, JY, Kaplan, LD, Levine, AM, Ramos, JC, Ambinder, RF, Wachsman, W, Aboulafia, D, Noy, A, Henry, DH, Von Roenn, J, Dezube, BJ, Remick, SC, Shah, MH, Leichman, L, Ratner, L, Cesarman, E, Chadburn, A & Mitsuyasu, R 2010, 'Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma', Blood, vol. 115, no. 15, pp. 3008-3016. https://doi.org/10.1182/blood-2009-08-231613
Sparano, Joseph A. ; Lee, Jeannette Y. ; Kaplan, Lawrence D. ; Levine, Alexandra M. ; Ramos, Juan Carlos ; Ambinder, Richard F. ; Wachsman, William ; Aboulafia, David ; Noy, Ariela ; Henry, David H. ; Von Roenn, Jamie ; Dezube, Bruce J. ; Remick, Scot C. ; Shah, Manisha H. ; Leichman, Lawrence ; Ratner, Lee ; Cesarman, Ethel ; Chadburn, Amy ; Mitsuyasu, Ronald. / Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. In: Blood. 2010 ; Vol. 115, No. 15. pp. 3008-3016.
@article{518211845515456690d375fc95168efe,
title = "Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma",
abstract = "Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIV-associated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73{\%}; 95{\%} confidence interval, 58{\%}-85{\%}) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55{\%}; 95{\%} confidence interval, 41{\%}-68{\%}) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm.We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.gov as NCT00049036.",
author = "Sparano, {Joseph A.} and Lee, {Jeannette Y.} and Kaplan, {Lawrence D.} and Levine, {Alexandra M.} and Ramos, {Juan Carlos} and Ambinder, {Richard F.} and William Wachsman and David Aboulafia and Ariela Noy and Henry, {David H.} and {Von Roenn}, Jamie and Dezube, {Bruce J.} and Remick, {Scot C.} and Shah, {Manisha H.} and Lawrence Leichman and Lee Ratner and Ethel Cesarman and Amy Chadburn and Ronald Mitsuyasu",
year = "2010",
month = "4",
day = "15",
doi = "10.1182/blood-2009-08-231613",
language = "English (US)",
volume = "115",
pages = "3008--3016",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

AU - Sparano, Joseph A.

AU - Lee, Jeannette Y.

AU - Kaplan, Lawrence D.

AU - Levine, Alexandra M.

AU - Ramos, Juan Carlos

AU - Ambinder, Richard F.

AU - Wachsman, William

AU - Aboulafia, David

AU - Noy, Ariela

AU - Henry, David H.

AU - Von Roenn, Jamie

AU - Dezube, Bruce J.

AU - Remick, Scot C.

AU - Shah, Manisha H.

AU - Leichman, Lawrence

AU - Ratner, Lee

AU - Cesarman, Ethel

AU - Chadburn, Amy

AU - Mitsuyasu, Ronald

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIV-associated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm.We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.gov as NCT00049036.

AB - Rituximab plus intravenous bolus chemotherapy is a standard treatment for immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have suggested that rituximab is associated with excessive toxicity in HIV-associated NHL, and that infusional chemotherapy may be more effective. We performed a randomized phase 2 trial of rituximab (375 mg/m2) given either concurrently before each infusional etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy cycle or sequentially (weekly for 6 weeks) after completion of all chemotherapy in HIV-associated NHL. EPOCH consisted of a 96-hour intravenous infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by intravenous bolus cyclophosphamide given every 21 days for 4 to 6 cycles. In the concurrent arm, 35 of 48 evaluable patients (73%; 95% confidence interval, 58%-85%) had a complete response. In the sequential arm, 29 of 53 evaluable patients (55%; 95% confidence interval, 41%-68%) had a complete response. The primary efficacy endpoint was met for the concurrent arm only. Toxicity was comparable in the 2 arms, although patients with a baseline CD4 count less than 50/μL had a high infectious death rate in the concurrent arm.We conclude that concurrent rituximab plus infusional EPOCH is an effective regimen for HIV-associated lymphoma. This study is registered at http://clinicaltrials.gov as NCT00049036.

UR - http://www.scopus.com/inward/record.url?scp=77951045842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951045842&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-08-231613

DO - 10.1182/blood-2009-08-231613

M3 - Article

C2 - 20023215

AN - SCOPUS:77951045842

VL - 115

SP - 3008

EP - 3016

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -